Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine

US8017785B2 · kind B2 · utility

Assignees

• ASTRAZENECA AB · SE
• Targacept, Inc. · US

Inventors

• Caroline Ericsson · Eslöv, SE
• Martin Bohlin · Stockholm, SE
• Tesfai Sebhatu · Malung, SE
• Gary Maurice Dull · Lewisville, US
• Julio A. Munoz · Walnut Cove, US
• Craig Harrison Miller · Winston-Salem, US

Key dates

• Filing date: May 8, 2007
• Grant date: Sep 13, 2011
• Expiry date: May 8, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.